New drug RC88 shows promise in early trial for hard-to-treat cancers

NCT ID NCT04175847

Completed Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at side effects, dosing limits, and early signs of effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma lung adenocarcinoma malignant pancreatic neoplasm malignant pleural mesothelioma ovarian carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Locations

Drum Tower Hospital

Nanjing, Jiangsu, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China